Angina Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Angina Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major angina markets reached a value of US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 10.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.7% during 2024-2034.

The angina market has been comprehensively analyzed in IMARC's new report titled "Angina Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Angina refers to a medical condition characterized by chest pain that develops when the heart muscle doesn't receive enough blood flow and oxygen. The pain is usually described as a squeezing, pressure, heaviness, tightness, or burning sensation in the chest, but it can also be felt in the arms, neck, jaw, shoulder, back, or stomach. Various other symptoms may include shortness of breath, sweating, nausea, dizziness, fatigue, etc. The pain or discomfort is triggered by physical activity, emotional stress, exposure to cold weather, or after a heavy meal, and tends to go away with rest. Diagnosing angina usually involves a medical history and physical examination to evaluate symptoms, risk factors, and a family history of heart disease. An electrocardiogram (ECG) is often performed to measure the electrical activity of the heart and look for any abnormalities. Numerous other procedures include a stress test to monitor the heart's response to physical activity, an echocardiogram to visualize the heart's structure and function, as well as blood tests to check for elevated levels of certain proteins or enzymes that indicate heart damage. Additionally, a coronary angiogram is also performed to view the coronary arteries and detect any blockages or narrowing that may be causing the angina symptoms.

The rising cases of coronary artery diseases, in which the arteries supplying blood to the heart muscle are blocked or narrowed due to the buildup of plaque, are primarily driving the angina market. In addition to this, the increasing prevalence of various risk factors, such as coronary artery spasm, aortic valve stenosis, hypertrophic cardiomyopathy, arrhythmias, anemia, emotional stress, etc., is also bolstering the market growth. Moreover, the widespread adoption of several medications, including nitroglycerin, beta-blockers, calcium channel blockers, etc., for reducing blood pressure and improving the heart's energy metabolism is acting as another significant growth-inducing factor. Besides this, the inflating demand for transcutaneous electrical nerve stimulation (TENS), which involves delivering a small electrical current to the nerves to reduce pain and discomfort associated with the ailment, is also creating a positive outlook for the market. Furthermore, the introduction of several enhanced drug delivery systems, including implantable drug delivery devices and targeted drug delivery systems, to improve the effectiveness of anti-anginal drugs is expected to drive the angina market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the angina market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for angina and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the angina market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the angina market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the angina market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current angina marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the angina market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the angina market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the angina market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of angina across the seven major markets?
What is the number of prevalent cases (2018-2034) of angina by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of angina by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of angina by type across the seven major markets?
How many patients are diagnosed (2018-2034) with angina across the seven major markets?
What is the size of the angina patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of angina?
What will be the growth rate of patients across the seven major markets?

Angina: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for angina drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the angina market?
What are the key regulatory events related to the angina market?
What is the structure of clinical trial landscape by status related to the angina market?
What is the structure of clinical trial landscape by phase related to the angina market?
What is the structure of clinical trial landscape by route of administration related to the angina market?